We are live on ! Find out more
ELTX icon

Elicio Therapeutics
ELTX

43 hedge funds and large institutions have $5.9M invested in Elicio Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.45% less ownership

Funds ownership: 2.18% → 1.73% (-0.45%)

9% less funds holding

Funds holding: 47 → 43 (-4)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

57% less capital invested

Capital invested by funds: $13.8M → $5.9M (-$7.95M)

69% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 16

Holders
43
Holders Change
-4
Holders Change %
-8.51%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
5
Reduced
16
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$293K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$217K
3
E
Ergoteles
New York
+$143K
4
PWAM
Park West Asset Management
California
+$121K
5
CM
CM Management
Florida
+$120K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.52M
2
State Street
State Street
Massachusetts
-$303K
3
JP Morgan Chase
JP Morgan Chase
New York
-$300K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$254K
5
Northern Trust
Northern Trust
Illinois
-$244K
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$19K +$27.2K +1,700 New
State Street
27
State Street
Massachusetts
$18K -$303K -18,979 -92%
CG
28
Caprock Group
Idaho
$18K – – –
SPIA
29
Steward Partners Investment Advisory
New York
$18K – – –
Qube Research & Technologies (QRT)
30
Qube Research & Technologies (QRT)
United Kingdom
$18K +$24.9K +1,562 New
YIH
31
Y-Intercept (HK)
Hong Kong
$13K +$17.8K +1,116 New
UBS Group
32
UBS Group
Switzerland
$12K +$16.8K +1,050 +2,234%
CC
33
Cannell Capital
Wyoming
$7K +$9.76K +611 New
Citigroup
34
Citigroup
New York
$4K -$6.47K -405 -51%
Barclays
35
Barclays
United Kingdom
$4K -$5.64K -353 -49%
Osaic Holdings
36
Osaic Holdings
Arizona
$3K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$1K -$5.65K -354 -76%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$1K -$463 -29 -30%
JP Morgan Chase
39
JP Morgan Chase
New York
– -$300K -14,185 Closed
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
– -$161K -7,601 Closed
Charles Schwab
41
Charles Schwab
California
– -$97K -4,575 Closed
Bank of New York Mellon
42
Bank of New York Mellon
New York
– -$91K -4,309 Closed
Nuveen
43
Nuveen
North Carolina
– -$69K -3,214 Closed
SO
44
STRS Ohio
Ohio
– -$41K -1,960 Closed
Deutsche Bank
45
Deutsche Bank
Germany
– -$29K -1,349 Closed
OQS
46
Occudo Quantitative Strategies
Florida
– -$27K -1,280 Closed
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
– -$25K -1,170 Closed
AIG
48
American International Group
New York
– -$23K -1,081 Closed
Two Sigma Investments
49
Two Sigma Investments
New York
– -$23K -1,073 Closed
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
– -$20K -956 Closed
1
2
3

ELTX Hedge Fund Activity: Q2 2022 in Review

43 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q2 2022, worth a combined $5.9M — down 57% from $13.8M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ELTX and 13 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 5 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $293K. The largest seller was BlackRock, cutting an estimated $1.52M.

  • 43 institutional investors held Elicio Therapeutics (ELTX) as of Q2 2022, down from 47 in Q1 2022.
  • Funds reported $5.9M of Elicio Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
  • 13 funds opened new Elicio Therapeutics positions in Q2 2022 and 16 closed out, a net change of -3 holders.
  • The largest Elicio Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $293K added.
  • The largest Elicio Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.52M sold.

Based on aggregated 13F filings for Q2 2022.